Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 373

Cited In for PubMed (Select 21696307)

1.
2.

Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.

Shaheen MA, Idrees M.

World J Hepatol. 2015 Mar 27;7(3):616-27. doi: 10.4254/wjh.v7.i3.616. Review.

3.

Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier.

Claveria-Gimeno R, Vega S, Grazu V, de la Fuente JM, Lanas A, Velazquez-Campoy A, Abian O.

Int J Nanomedicine. 2015 Mar 19;10:2249-59. doi: 10.2147/IJN.S79480. eCollection 2015.

4.

Impairment of Type I but Not Type III IFN Signaling by Hepatitis C Virus Infection Influences Antiviral Responses in Primary Human Hepatocytes.

Friborg J, Ross-Macdonald P, Cao J, Willard R, Lin B, Eggers B, McPhee F.

PLoS One. 2015 Mar 31;10(3):e0121734. doi: 10.1371/journal.pone.0121734. eCollection 2015.

5.

Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy.

Urraro T, Gragnani L, Piluso A, Fabbrizzi A, Monti M, Fognani E, Boldrini B, Ranieri J, Zignego AL.

Case Reports Immunol. 2015;2015:816424. doi: 10.1155/2015/816424. Epub 2015 Mar 1.

6.

Serum Interferon-Related MicroRNAs as Biomarkers to Predict the Response to Interferon Therapy in Chronic Hepatitis C Genotype 4.

Motawi TK, Shaker OG, El-Maraghy SA, Senousy MA.

PLoS One. 2015 Mar 19;10(3):e0120794. doi: 10.1371/journal.pone.0120794. eCollection 2015.

7.

Telaprevir experience from Turkey.

Komur S, Kurtaran B, Inal AS, Pullukcu H, Ulu A, Kuscu F, Yamazhan T, Tasova Y, Aksu HS.

Hepat Mon. 2015 Feb 18;15(2):e25639. doi: 10.5812/hepatmon.25639. eCollection 2015 Feb.

8.

IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients.

Bertol BC, Moreira S, Garcia RF, Ferreira LE, Debortoli G, Pinho Mde S, Amendola-Pires M, Maciel AM, Brandço-Mello CE, de França PH.

Front Microbiol. 2015 Mar 4;6:153. doi: 10.3389/fmicb.2015.00153. eCollection 2015.

9.

Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?

Dhiman RK.

J Clin Exp Hepatol. 2014 Jun;4(2):85-6. doi: 10.1016/j.jceh.2014.06.011. No abstract available.

10.

High Incidence of Telaprevir-associated Severe Rash Leading to Discontinuation.

Núñez M.

J Clin Exp Hepatol. 2013 Mar;3(1):86. doi: 10.1016/j.jceh.2012.12.002. No abstract available.

11.

The hepatitis C genotype 1 paradox: Cost per treatment is increasing, but cost per cure is decreasing.

Shafran SD.

Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):46-8.

PMID:
25706574
12.

Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C.

Iijima S, Matsuura K, Watanabe T, Onomoto K, Fujita T, Ito K, Iio E, Miyaki T, Fujiwara K, Shinkai N, Kusakabe A, Endo M, Nojiri S, Joh T, Tanaka Y.

PLoS One. 2015 Feb 23;10(2):e0118000. doi: 10.1371/journal.pone.0118000. eCollection 2015.

13.

Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.

Satoh S, Mori K, Ueda Y, Sejima H, Dansako H, Ikeda M, Kato N.

PLoS One. 2015 Feb 20;10(2):e0118313. doi: 10.1371/journal.pone.0118313. eCollection 2015.

14.

Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection.

Nguyen DL, Morgan TR.

Clin Liver Dis (Hoboken). 2012 Apr;1(2):54-57. No abstract available.

15.

Retreatment with peginterferon and ribavirin in chronic hepatitis C.

Jo YM, Lee SW, Han SY, Baek YH, Kim SY, Kim WJ, Ahn JH, Lee JY.

World J Gastroenterol. 2015 Feb 14;21(6):1994-9. doi: 10.3748/wjg.v21.i6.1994.

16.

"Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign.

Coughlin SS.

JMIR Res Protoc. 2015 Feb 6;4(1):e13. doi: 10.2196/resprot.3822.

17.

Treatment of chronic hepatitis C in patients with HIV/HCV coinfection.

Coppola N, Martini S, Pisaturo M, Sagnelli C, Filippini P, Sagnelli E.

World J Virol. 2015 Feb 12;4(1):1-12. doi: 10.5501/wjv.v4.i1.1. Review.

18.
19.

Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Wu LS, Rower JE, Burton JR Jr, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ.

Antimicrob Agents Chemother. 2015 Apr;59(4):2179-88. doi: 10.1128/AAC.04618-14. Epub 2015 Feb 2.

PMID:
25645847
20.

Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C.

McEwan P, Ward T, Bennett H, Kalsekar A, Webster S, Brenner M, Yuan Y.

PLoS One. 2015 Jan 30;10(1):e0117334. doi: 10.1371/journal.pone.0117334. eCollection 2015.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk